News Release

Moffitt researchers analyze VA data to study prostate cancer disparities

"Equal access system” shows how African American men are disproportionately affected

Peer-Reviewed Publication

H. Lee Moffitt Cancer Center & Research Institute

TAMPA, Fla. Prostate cancer is one of the most common cancers in American men, second only to skin cancer. One in eight men will develop the disease in his lifetime. While nearly 250,000 men will be diagnosed with prostate cancer each year, research has shown that the disease is often more aggressive and more deadly for African American men.

Moffitt Cancer Center has been conducting research on disparities in prostate cancer, specifically evaluating the interplay between social and biological mechanisms that drive the disease among different races and ethnicities, for many years.

The newest study, published by JAMA Network Open, is a collaboration with the Prostate Cancer Foundation, the Veterans Affairs, and John and Daria Barry Foundation Precision Oncology Center of Excellence. Dr. Kosj Yamoah and his team evaluated 7.8 million veterans nationwide who were treated for prostate cancer between 2005 and 2019 with the goal of assessing racial disparities.

“The VA provides high-quality care to veterans regardless of race, sex, geographic location or economic circumstance, thereby creating an equal access system compared to other large health care systems. This provides us with a unique environment to investigate prostate cancer health disparities across the disease continuum, such as treatment response or overall outcomes at each phase of the disease,” said Yamoah, director of Radiation Oncology Cancer Health Disparities Research and section head of Genitourinary Oncology within the Department of Radiation Oncology at Moffitt.

The results of this nationwide retrospective analysis showed that African American veterans had a nearly two-fold greater incidence of prostate cancer, both localized disease and de novo metastatic disease, compared to European American men. African American men also had a 29% increased risk of prostate cancer detection on diagnostic prostate biopsy compared to European American men.

From a treatment perspective, African American men who received definitive primary treatment in a timely fashion experienced a lower risk of metastasis. But those who did not receive treatment right away or did not have any clear documentation of treatment had a worse risk of developing metastatic disease.

Yamoah says the findings more clearly define the drivers of prostate cancer disparities within a nearly equal access setting and highlights the need for action.

“Increased incidence of prostate cancer is a major driver of the residual disparity in prostate cancer metastasis among African American men. Even in an equal access to care scenario, we saw that adequate, timely therapy is a big factor that will decrease the risk of adverse events, including metastases and death,” he said.  “There is a lot of work still to be done, but this data gives us the information we need to develop strategies to combat prostate cancer disparities here in the U.S. and globally.”

This study was supported by the Jean Perkins Foundation, STOP Cancer Foundation, National Cancer Institute (P50CA092131 and P20CA233255), the Prostate Cancer Foundation (17CHALO4) and the U.S. Department of Defense (W81XWH-19-1-0435).

About Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 52 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 7,500 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit, and follow the momentum on Facebook, Twitter, Instagram and YouTube



Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.